BioPharma Credit Pink Sheet Forecast - Naive Prediction
| BOPCFDelisted Stock | USD 0.92 0.00 0.00% |
The Naive Prediction forecasted value of BioPharma Credit PLC on the next trading day is expected to be 0.90 with a mean absolute deviation of 0.01 and the sum of the absolute errors of 0.46. BioPharma Pink Sheet Forecast is based on your current time horizon. We recommend always using this module together with an analysis of BioPharma Credit's historical fundamentals, such as revenue growth or operating cash flow patterns.
As of 25th of January 2026 the relative strength index (rsi) of BioPharma Credit's share price is below 20 suggesting that the pink sheet is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
Using BioPharma Credit hype-based prediction, you can estimate the value of BioPharma Credit PLC from the perspective of BioPharma Credit response to recently generated media hype and the effects of current headlines on its competitors.
The Naive Prediction forecasted value of BioPharma Credit PLC on the next trading day is expected to be 0.90 with a mean absolute deviation of 0.01 and the sum of the absolute errors of 0.46. BioPharma Credit after-hype prediction price | USD 0.92 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
BioPharma |
BioPharma Credit Additional Predictive Modules
Most predictive techniques to examine BioPharma price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for BioPharma using various technical indicators. When you analyze BioPharma charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
BioPharma Credit Naive Prediction Price Forecast For the 26th of January
Given 90 days horizon, the Naive Prediction forecasted value of BioPharma Credit PLC on the next trading day is expected to be 0.90 with a mean absolute deviation of 0.01, mean absolute percentage error of 0.0001, and the sum of the absolute errors of 0.46.Please note that although there have been many attempts to predict BioPharma Pink Sheet prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that BioPharma Credit's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
BioPharma Credit Pink Sheet Forecast Pattern
| Backtest BioPharma Credit | BioPharma Credit Price Prediction | Buy or Sell Advice |
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of BioPharma Credit pink sheet data series using in forecasting. Note that when a statistical model is used to represent BioPharma Credit pink sheet, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 109.068 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0076 |
| MAPE | Mean absolute percentage error | 0.0084 |
| SAE | Sum of the absolute errors | 0.462 |
Predictive Modules for BioPharma Credit
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BioPharma Credit PLC. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of BioPharma Credit's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
BioPharma Credit After-Hype Price Prediction Density Analysis
As far as predicting the price of BioPharma Credit at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in BioPharma Credit or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of BioPharma Credit, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
BioPharma Credit Estimiated After-Hype Price Volatility
In the context of predicting BioPharma Credit's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on BioPharma Credit's historical news coverage. BioPharma Credit's after-hype downside and upside margins for the prediction period are 0.05 and 2.65, respectively. We have considered BioPharma Credit's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
BioPharma Credit is very risky at this time. Analysis and calculation of next after-hype price of BioPharma Credit PLC is based on 3 months time horizon.
BioPharma Credit Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as BioPharma Credit is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioPharma Credit backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with BioPharma Credit, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.08 | 1.73 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | In 5 to 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.92 | 0.92 | 0.00 |
|
BioPharma Credit Hype Timeline
BioPharma Credit PLC is currently traded for 0.92. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. BioPharma is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at -0.08%. %. The volatility of related hype on BioPharma Credit is about 0.0%, with the expected price after the next announcement by competition of 0.92. About 39.0% of the company shares are held by institutions such as insurance companies. The company had not issued any dividends in recent years. Assuming the 90 days horizon the next forecasted press release will be in 5 to 10 days. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.BioPharma Credit Related Hype Analysis
Having access to credible news sources related to BioPharma Credit's direct competition is more important than ever and may enhance your ability to predict BioPharma Credit's future price movements. Getting to know how BioPharma Credit's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how BioPharma Credit may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| IHPGF | IntegraFin Holdings plc | 0.00 | 0 per month | 0.00 | (0.01) | 0.00 | 0.00 | 8.17 | |
| GCAAF | Guardian Capital Group | 0.00 | 0 per month | 0.24 | (0.07) | 0.59 | (0.65) | 2.26 | |
| PTZIF | Patrizia AG | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| RTOBF | Ratos AB | 0.00 | 0 per month | 0.00 | 0.11 | 0.00 | 0.00 | 81.41 | |
| CNECF | Centuria Capital Group | 0.00 | 0 per month | 0.00 | (0.04) | 0.00 | 0.00 | 5.91 | |
| LNTQF | Leonteq AG | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| UCPLF | Uniteds Limited | 0.00 | 0 per month | 0.00 | 0.01 | 0.00 | 0.00 | 8.68 | |
| IOOFF | IOOF Holdings | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| BOMXF | Bolsa Mexicana de | 0.00 | 0 per month | 1.34 | 0.05 | 4.50 | (1.96) | 18.74 | |
| LRCDF | Laurentian Bank of | 0.00 | 0 per month | 0.54 | 0.14 | 1.38 | (1.24) | 18.76 |
BioPharma Credit Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioPharma Credit pink sheet to make a market-neutral strategy. Peer analysis of BioPharma Credit could also be used in its relative valuation, which is a method of valuing BioPharma Credit by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
BioPharma Credit Market Strength Events
Market strength indicators help investors to evaluate how BioPharma Credit pink sheet reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading BioPharma Credit shares will generate the highest return on investment. By undertsting and applying BioPharma Credit pink sheet market strength indicators, traders can identify BioPharma Credit PLC entry and exit signals to maximize returns.
BioPharma Credit Risk Indicators
The analysis of BioPharma Credit's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in BioPharma Credit's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting biopharma pink sheet prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 0.6709 | |||
| Standard Deviation | 1.51 | |||
| Variance | 2.27 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for BioPharma Credit
The number of cover stories for BioPharma Credit depends on current market conditions and BioPharma Credit's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that BioPharma Credit is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about BioPharma Credit's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in BioPharma Pink Sheet
If you are still planning to invest in BioPharma Credit PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BioPharma Credit's history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |